Moore Capital Management LP Acquires New Position in Repligen Corporation $RGEN

Moore Capital Management LP acquired a new stake in Repligen Corporation (NASDAQ:RGEN) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 37,549 shares of the biotechnology company’s stock, valued at approximately $5,123,000. Moore Capital Management LP owned approximately 0.07% of Repligen at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Thornburg Investment Management Inc. raised its holdings in shares of Repligen by 49.3% in the 2nd quarter. Thornburg Investment Management Inc. now owns 43,887 shares of the biotechnology company’s stock valued at $5,988,000 after purchasing an additional 14,486 shares in the last quarter. Van ECK Associates Corp boosted its position in shares of Repligen by 173.8% during the 2nd quarter. Van ECK Associates Corp now owns 17,887 shares of the biotechnology company’s stock worth $2,441,000 after acquiring an additional 11,354 shares in the last quarter. Hsbc Holdings PLC raised its position in shares of Repligen by 22.2% during the 2nd quarter. Hsbc Holdings PLC now owns 24,170 shares of the biotechnology company’s stock worth $3,302,000 after acquiring an additional 4,398 shares in the last quarter. North Star Asset Management Inc. purchased a new stake in Repligen during the second quarter worth approximately $10,582,000. Finally, United Capital Financial Advisors LLC acquired a new position in Repligen in the second quarter valued at approximately $380,756,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on RGEN. Weiss Ratings raised Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, August 13th. HSBC cut their target price on shares of Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a report on Wednesday, June 3rd. Wolfe Research started coverage on shares of Repligen in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 price target for the company. Zacks Research raised shares of Repligen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. Finally, Evercore restated an “outperform” rating and issued a $160.00 price objective on shares of Repligen in a research note on Monday, July 6th. Three analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, Repligen currently has an average rating of “Buy” and an average target price of $166.43.

Insider Buying and Selling at Repligen

In related news, CFO Jason K. Garland sold 733 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the sale, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. This represents a 3.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.60% of the company’s stock.

Repligen Trading Up 2.7%

Shares of RGEN opened at $180.98 on Tuesday. Repligen Corporation has a one year low of $100.99 and a one year high of $188.73. The stock has a 50-day moving average price of $153.08 and a 200 day moving average price of $133.28. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. The company has a market capitalization of $10.21 billion, a P/E ratio of 247.92, a P/E/G ratio of 3.22 and a beta of 1.03.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The company had revenue of $204.13 million during the quarter, compared to analyst estimates of $201.59 million. During the same period last year, the business earned $0.26 EPS. The firm’s revenue for the quarter was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Sell-side analysts forecast that Repligen Corporation will post 2.06 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.